Clinical

Dataset Information

0

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain


ABSTRACT: This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain. The study medication is administered under the tongue as a simple spray and can be self-administered by patients or assisted by their caregivers. Patients are titrated to an effective-dose of fentanyl sublingual spray in the open-label titration period and then proceed to the double-blind randomized period where they randomly receive 7 treatments with fentanyl sublingual spray and 3 treatments with placebo. Patients are treated for up to a total of 6-7 weeks (including both the open-label titration and the double-blind randomized periods).

DISEASE(S): Extramedullary Plasmacytoma,Primary Myelofibrosis,Pain,Cancer Pain,Angioimmunoblastic T-cell Lymphoma,Monoclonal Gammopathy Of Undetermined Significance,Cancer

PROVIDER: 2044922 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2018-09-17 | GSE99802 | GEO
2020-09-01 | GSE137430 | GEO
2022-11-08 | PXD034803 | Pride
2024-05-17 | GSE232408 | GEO
2021-12-22 | GSE155665 | GEO
2018-10-06 | GSE120899 | GEO
2010-06-11 | E-GEOD-7877 | biostudies-arrayexpress
2009-01-20 | E-GEOD-11355 | biostudies-arrayexpress
2010-08-17 | E-GEOD-14700 | biostudies-arrayexpress
2017-07-07 | GSE100833 | GEO